STRO
USDSutro Biopharma Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$1.240
고가
$1.240
저가
$0.832
거래량
0.04M
기업 기본 정보
시가총액
108.9M
산업
생명공학
국가
United States
거래 통계
평균 거래량
1.76M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma from Buy to Neutral and lowers the price target from $12 to $2.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),
Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform
Citizens Capital Markets analyst Reni Benjamin downgrades Sutro Biopharma from Market Outperform to Market Perform.
Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
Wedbush analyst David Nierengarten downgrades Sutro Biopharma from Outperform to Neutral and lowers the price target from $8 to $2.
B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1
B of A Securities analyst Tazeen Ahmad downgrades Sutro Biopharma from Buy to Underperform and lowers the price target from $11 to $1.
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug
